Oncology Med Will Begin Servicing New Multiple Year Contract With Large Physician Owned Surgery Center in Metro Boston Area This
10 7월 2008 - 10:45PM
Marketwired
PITTSBURGH, PA , a Pittsburgh-based cancer treatment solutions
group, announced today that during this month of July, 2008 it will
begin providing prostate cancer brachytherapy treatment services
under a new multiple year exclusive contract with Eastern
Massachusetts Ambulatory Surgery Center; a physician owned surgery
center being managed by Ambulatory Surgery Centers of America with
affiliate facilities located throughout the United States.
Activities of the Company will include providing physics and full
turnkey prostate cancer brachytherapy services, equipment, staff,
and radionuclide seed management to the surgery center and
affiliated radiation oncologists.
According to William Walker, Ph.D., Oncology Med's CEO and
founder, "This new contract is projected to provide us with
approximately 80 cases annually. We are additionally in discussions
with several other ambulatory surgical centers in the surrounding
areas and hope to announce additional contracts shortly."
Jack Sloan, Vice President of Business Development, added, "We
will continue to expand our ambulatory surgery center turnkey
programs as we diversify our company and role out additional
turnkey programs and services to our target customers such as our
new turnkey complete cancer center model for physicians and other
interested investors for the design and implementation of new
'centers of excellence' cancer treatment centers which we recently
announced. This is just another of our programs where OMI can shine
as a cutting edge provider of services supplying nearly all of the
clinical and technical services from within OMI and where
outsourcing is kept to a minimum allowing for high quality delivery
of all necessary components in the fastest time for the lowest
cost."
"Our ambulatory surgery center (ASC) prostate brachytherapy
programs have been both clinically and financially successful for
OMI mainly due to our speed of implementation after contract
execution and clinically excellent services provided to the surgery
centers and physicians," he continued.
Walker added, "In addition to our ASC programs, we are seeing a
substantial increase in the number of free standing cancer centers
being developed. We will continue to place our Company in a
competitive position to provide the desired and needed services to
these clients for continued financial success of Oncology Med in
our quest to aggressively expand our footprint in the cancer
treatment market through additional long term contracts with local
and national clients that are viable and a good fit for our Company
and the services we provide. In addition, we will continue to add
internal services and staff to meet those goals and to be able to
remain a competitive force in the industry."
In addition to physics staffing and support, Oncology Med
continues to expand and provide extensive consultation services for
new and expanded cancer center construction, certification, and
credentialing processes for Joint Commission, as well as, complete
turnkey programs for continuation or implementation of radiation
treatment programs for ambulatory surgery centers, radiation
oncologists, urologists, and hospitals.
All inquiries for Oncology Med's programs and services should be
made to its administrative offices at: Oncology Med, Inc., 11928
Ropp Lane, Lovettsville, VA 20180. Phone: (540) 822-5161
About Oncology Med, Inc.
Oncology Med is a public company engaged in the fulfillment of
services related to the treatment of various cancers. It currently
provides analysis and design of radiation treatment plans in order
for radiation oncologists to administer radiation treatments to
cancer patients. Current services facilitate radiation treatment
programs ranging from external beam radiation to more advanced
radiation treatment technologies.
More information about Oncology Med, Inc. can be found at
www.oncologymed.com.
NOTE: This press release may contain "forward-looking
statements." In some cases, you can identify forward-looking
statements by terminology such as "may," "will," "should," "could,"
"expects," "plans," "intends," "anticipates," "believes,"
"estimates," "predicts," "potential," "continue" or the negative of
such terms and other comparable terminology. These forward-looking
statements include, without limitation, statements about our market
opportunity, our strategies, competition, expected activities and
expenditures as we pursue our business plan, and the adequacy of
our available cash resources. Although we believe that the
expectations reflected in any forward-looking statements are
reasonable, we cannot guarantee future results, levels of activity,
performance or achievements. Actual results may differ materially
from the predictions discussed in these forward-looking statements.
Changes in the circumstances upon which we base our predictions
and/or forward-looking statements could materially affect our
actual results.
For information, please contact: William 'Bill' Walker CEO (540)
822-5161 Email Contact
Bellatora (PK) (USOTC:ECGR)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Bellatora (PK) (USOTC:ECGR)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
